短链脂肪酸在神经退行性疾病中的相关机制研究进展

doi:10.12114/j.issn.1007-9572.2022.0783

中国全科医学 ›› 2023, Vol. 26 ›› Issue (24): 3061-3066.DOI: 10.12114/j.issn.1007-9572.2022.0783

短链脂肪酸在神经退行性疾病中的相关机制研究进展

朱莉¹, 幸佳佳¹, 魏娟芳¹, 王文春², 张安仁³^,^*()

1．610075　四川省成都市，成都中医药大学养生康复学院
2．610083　四川省成都市，中国人民解放军西部战区总医院康复医学科
3．200434　上海市，同济大学附属上海市第四人民医院康复医学科

收稿日期:2022-09-15 修回日期:2022-12-26 出版日期:2023-08-20 发布日期:2022-12-30
通讯作者: 张安仁
作者贡献：朱莉进行文章的构思，负责撰写论文；幸佳佳、魏娟芳负责文献/资料收集、整理；王文春进行论文修订；张安仁负责文章质量控制及审校，对文章整体负责。
基金资助:
国家自然科学基金资助项目(81973927)

Research Advances in the Mechanism of Short-chain Fatty Acids in Neurodegenerative Diseases

ZHU Li¹, XING Jiajia¹, WEI Juanfang¹, WANG Wenchun², ZHANG Anren³^,^*()

1. School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
2. Department of Rehabilitation Medicine, Chinese People's Liberation Army Western Theater General Hospital, Chengdu 610083, China
3. Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai 200434, China

Received:2022-09-15 Revised:2022-12-26 Published:2023-08-20 Online:2022-12-30
Contact: ZHANG Anren

分享到

摘要/Abstract

摘要： 神经退行性疾病是中枢神经系统中神经元功能或结构进行性丧失而导致的一组疾病，虽然神经退行性疾病的身体或精神症状可通过联合治疗来缓解，但目前还没有直接减缓或预防神经退行性疾病的策略。近年来对肠道微生物群-肠-脑轴研究发现，肠道微生物群及其代谢产物在神经系统疾病的发生、发展中发挥着重要作用，而短链脂肪酸作为肠道微生物群的主要代谢产物，是肠-脑沟通的关键递质，对神经退行性疾病具有神经保护作用，但其具体机制尚不清楚。本文主要综述了短链脂肪酸对神经退行性疾病的作用机制，得出通过改变饮食习惯增加膳食纤维的摄入含量、补充益生菌与外源性短链脂肪酸等方法从而改变体内短链脂肪酸水平，可能会成为神经退行性疾病安全有效的防治新靶点，以期为神经退行性疾病的治疗提供参考。

关键词: 神经变性疾病, 短链脂肪酸, 氧化应激, 线粒体功能, 神经炎症, 小胶质细胞

Abstract:

Neurodegenerative diseases are a group of conditions caused by the progressive loss of the function or structure of neurons in the central nervous system. Although the physical or mental symptoms of neurodegenerative diseases can be alleviated by combined therapy, there is no strategy to directly slow down or prevent neurodegenerative diseases. Recent studies on the microbiota-gut-brain axis have found that gut microbiota and their metabolites play an important role in the occurrence and development of nervous system diseases. As the main metabolites of gut microbiota, short-chain fatty acids (SCFAs) , are the key transmitter involved in gut-brain communication and have neuroprotective effect on neurodegenerative diseases, but the specific mechanism is not clear. This article mainly reviews the mechanism of SCFAs in neurodegenerative diseases. It is concluded that improving the level of SCFAs in vivo by changing dietary habits via increasing dietary fiber intake and supplementing probiotics and exogenous SCFAs, may become a new safe and effective target for the prevention and treatment of neurodegenerative diseases, which may provide guidance for the treatment of neurodegenerative diseases.

Key words: Neurodegenerative diseases, Short-chain fatty acids, Oxidative stress, Mitochondrial function, Neuroinflammation, Microglia

朱莉,幸佳佳,魏娟芳,等. 短链脂肪酸在神经退行性疾病中的相关机制研究进展[J]. 中国全科医学, 2023, 26(24): 3061-3066. DOI: 10.12114/j.issn.1007-9572.2022.0783.
ZHU Li,XING Jiajia,WEI Juanfang, et al. Research Advances in the Mechanism of Short-chain Fatty Acids in Neurodegenerative Diseases[J]. Chinese General Practice, 2023, 26(24): 3061-3066. DOI: 10.12114/j.issn.1007-9572.2022.0783.

参考文献 53

[1]	CUMMINGS J. Disease modification and Neuroprotection in neurodegenerative disorders[J]. Transl Neurodegener，2017,6:25. DOI：10.1186/s40035-017-0096-2.
[2]	HEEMELS M T. Neurodegenerative diseases[J]. Nature，2016,539(7628):179. DOI：10.1038/539179a.
[3]	DAWSON T M, GOLDE T E, LAGIER-TOURENNE C. Animal models of neurodegenerative diseases[J]. Nat Neurosci，2018,21(10):1370-1379. DOI：10.1038/s41593-018-0236-8.
[4]	BD N, R K D, SK M. Gut microbial molecules in behavioural and neurodegenerative conditions[J]. Nat Rev Neurosci，2020,21(12):717-731. DOI：10.1038/s41583-020-00381-0.
[5]	MILLER T L, WOLIN M J. Pathways of acetate，propionate，and butyrate formation by the human fecal microbial flora[J]. Appl Environ Microbiol，1996,62(5):1589-1592. DOI：10.1128/aem.62.5.1589-1592.1996.
[6]	CUMMINGS J H, POMARE E W, BRANCH W J，et al. Short chain fatty acids in human large intestine，portal，hepatic and venous blood[J]. Gut，1987,28(10):1221-1227. DOI：10.1136/gut.28.10.1221.
[7]	TAGLIABUE A, ELLI M. The role of gut microbiota in human obesity：recent findings and future perspectives[J]. Nutr Metab Cardiovasc Dis，2013,23(3):160-168. DOI：10.1016/j.numecd.2012.09.002.
[8]	DONOHOE D R, GARGE N, ZHANG X X，et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon[J]. Cell Metab，2011,13(5):517-526. DOI：10.1016/j.cmet.2011.02.018.
[9]	BRAHE L K, ASTRUP A, LARSEN L H. Is butyrate the link between diet，intestinal microbiota and obesity-related metabolic diseases?[J]. Obes Rev，2013,14(12):950-959. DOI：10.1111/obr.12068.
[10]	BURGER-VAN PAASSEN N, VINCENT A, PUIMAN P J，et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids：implications for epithelial protection[J]. Biochem J，2009,420(2):211-219. DOI：10.1042/BJ20082222.
[11]	LU J, ZHENG J, WANG B H，et al. The human microbiota in health and disease[J]. Engineering，2017,3(1):71-82. DOI：10.1016/J.ENG.2017.01.008.
[12]	PEREZ-PARDO P, DODIYA H B, ENGEN P A，et al. Role of TLR4 in the gut-brain axis in Parkinson's disease：a translational study from men to mice[J]. Gut，2019,68(5):829-843. DOI：10.1136/gutjnl-2018-316844.
[13]	UNGER M M, SPIEGEL J, DILLMANN K U，et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls[J]. Parkinsonism Relat Disord，2016,32:66-72. DOI：10.1016/j.parkreldis.2016.08.019.
[14]	ZHANG L, WANG Y, XIAYU X，et al. Altered gut microbiota in a mouse model of Alzheimer's disease[J]. J Alzheimers Dis，2017,60(4):1241-1257. DOI：10.3233/jad-170020.
[15]	ZHENG J, ZHENG S J, CAI W J，et al. Stable isotope labeling combined with liquid chromatography-tandem mass spectrometry for comprehensive analysis of short-chain fatty acids[J]. Anal Chim Acta，2019,1070:51-59. DOI：10.1016/j.aca.2019.04.021.
[16]	ZENG Q, GONG J L, LIU X Y，et al. Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis[J]. Neurochem Int，2019,129:104468. DOI：10.1016/j.neuint.2019.104468.
[17]	DUGGER B N, DICKSON D W. Pathology of neurodegenerative diseases[J]. Cold Spring Harb Perspect Biol，2017,9(7):a028035. DOI：10.1101/cshperspect.a028035.
[18]	HUSSAIN R, ZUBAIR H, PURSELL S，et al. Neurodegenerative diseases：regenerative mechanisms and novel therapeutic approaches[J]. Brain Sci，2018,8(9):177. DOI：10.3390/brainsci8090177.
[19]	HO L, ONO K, TSUJI M，et al. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms[J]. Expert Rev Neurother，2018,18(1):83-90. DOI：10.1080/14737175.2018.1400909.
[20]	FERNANDO W M A D B, MARTINS I J, MORICI M，et al. Sodium butyrate reduces brain amyloid-β levels and improves cognitive memory performance in an Alzheimer's disease transgenic mouse model at an early disease stage[J]. J Alzheimers Dis，2020,74(1):91-99. DOI：10.3233/JAD-190120.
[21]	MARIZZONI M, CATTANEO A, MIRABELLI P，et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer's disease[J]. J Alzheimers Dis，2020,78(2):683-697. DOI：10.3233/JAD-200306.
[22]	QIAO C M, SUN M F, JIA X B，et al. Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway[J]. Exp Cell Res，2020,387(1):111772. DOI：10.1016/j.yexcr.2019.111772.
[23]	HOU Y C, LI X Q, LIU C，et al. Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease[J]. Exp Gerontol，2021,150:111376. DOI：10.1016/j.exger.2021.111376.
[24]	BAGHERI F, KHORI V, ALIZADEH A M，et al. Reactive oxygen species-mediated cardiac-reperfusion injury：mechanisms and therapies[J]. Life Sci，2016,165:43-55. DOI：10.1016/j.lfs.2016.09.013.
[25]	ADIBHATLA R M, HATCHER J F. Lipid oxidation and peroxidation in CNS health and disease：from molecular mechanisms to therapeutic opportunities[J]. Antioxid Redox Signal，2010,12(1):125-169. DOI：10.1089/ars.2009.2668.
[26]	BHAT A H, DAR K B, ANEES S，et al. Oxidative stress，mitochondrial dysfunction and neurodegenerative diseases；a mechanistic insight[J]. Biomed Pharmacother，2015,74:101-110. DOI：10.1016/j.biopha.2015.07.025.
[27]	YAMAMOTO M, KENSLER T W, MOTOHASHI H. The KEAP1-NRF2 system：a thiol-based sensor-effector apparatus for maintaining redox homeostasis[J]. Physiol Rev，2018,98(3):1169-1203. DOI：10.1152/physrev.00023.2017.
[28]	MANN G E, FORMAN H J. Introduction to special issue on 'Nrf2 regulated redox signaling and metabolism in physiology and medicine[J]. Free Radic Biol Med，2015,88(Pt B):91-92. DOI：10.1016/j.freeradbiomed.2015.08.002.
[29]	TEBAY L E, ROBERTSON H, DURANT S T，et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors，nutrient cues，and energy status and the pathways through which it attenuates degenerative disease[J]. Free Radic Biol Med，2015,88(Pt B):108-146. DOI：10.1016/j.freeradbiomed.2015.06.021.
[30]	WU J D, JIANG Z P, ZHANG H N，et al. Sodium butyrate attenuates diabetes-induced aortic endothelial dysfunction via P300-mediated transcriptional activation of Nrf2[J]. Free Radic Biol Med，2018,124:454-465. DOI：10.1016/j.freeradbiomed.2018.06.034.
[31]	DUMITRESCU L, POPESCU-OLARU I, COZMA L，et al. Oxidative stress and the microbiota-gut-brain axis[J]. Oxid Med Cell Longev，2018,2018:2406594. DOI：10.1155/2018/2406594.
[32]	SZCZECHOWIAK K, DINIZ B S, LESZEK J. Diet and Alzheimer's dementia - Nutritional approach to modulate inflammation[J]. Pharmacol Biochem Behav，2019,184:172743. DOI：10.1016/j.pbb.2019.172743.
[33]	GENG X, YANG B, LI R T，et al. Effects of docosahexaenoic acid and its peroxidation product on amyloid-β peptide-stimulated microglia[J]. Mol Neurobiol，2020,57(2):1085-1098. DOI：10.1007/s12035-019-01805-4.
[34]	HOYLES L, SNELLING T, UMLAI U K，et al. Microbiome-host systems interactions：protective effects of propionate upon the blood-brain barrier[J]. Microbiome，2018,6(1):55. DOI：10.1186/s40168-018-0439-y.
[35]	NURRAHMA B A, TSAO S P, WU C H，et al. Probiotic supplementation facilitates recovery of 6-OHDA-induced motor deficit via improving mitochondrial function and energy metabolism[J]. Front Aging Neurosci，2021,13:668775. DOI：10.3389/fnagi.2021.668775.
[36]	FILIPPONE A, LANZA M, CAMPOLO M，et al. The anti-inflammatory and antioxidant effects of sodium propionate[J]. Int J Mol Sci，2020,21(8):3026. DOI：10.3390/ijms21083026.
[37]	AGUILAR E C, SANTOS L C, LEONEL A J，et al. Oral butyrate reduces oxidative stress in atherosclerotic lesion sites by a mechanism involving NADPH oxidase down-regulation in endothelial cells[J]. J Nutr Biochem，2016,34:99-105. DOI：10.1016/j.jnutbio.2016.05.002.
[38]	LI H R, UITTENBOGAARD M, HAO L，et al. Clinical insights into mitochondrial neurodevelopmental and neurodegenerative disorders：their biosignatures from mass spectrometry-based metabolomics[J]. Metabolites，2021,11(4):233. DOI：10.3390/metabo11040233.
[39]	施蕴渝，张亮. 线粒体与神经退行性疾病[J]. 生物学杂志，2022,39(2):1-10.
[40]	TANG Y, CHEN Y, JIANG H，et al. Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death[J]. Cell Death Differ，2011,18(4):602-618. DOI：10.1038/cdd.2010.117.
[41]	ROSE S, BENNURI S C, DAVIS J E，et al. Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism[J]. Transl Psychiatry，2018,8:42. DOI：10.1038/s41398-017-0089-z.
[42]	WANG C, ZHENG D P, WENG F L，et al. Sodium butyrate ameliorates the cognitive impairment of Alzheimer's disease by regulating the metabolism of astrocytes[J]. Psychopharmacology，2022,239(1):215-227. DOI：10.1007/s00213-021-06025-0.
[43]	LIU Z G, DAI X S, ZHANG H B，et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment[J]. Nat Commun，2020,11(1):855. DOI：10.1038/s41467-020-14676-4.
[44]	DUSCHA A, GISEVIUS B, HIRSCHBERG S，et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism[J]. Cell，2020,180(6):1067-1080.e16. DOI：10.1016/j.cell.2020.02.035.
[45]	LAGO-BALDAIA I, FERNANDES V M, ACKERMAN S D. More than mortar：Glia as architects of nervous system development and disease[J]. Front Cell Dev Biol，2020,8:611269. DOI：10.3389/fcell.2020.611269.
[46]	VILLA A, VEGETO E, POLETTI A，et al. Estrogens，neuroinflammation，and neurodegeneration[J]. Endocr Rev，2016,37(4):372-402. DOI：10.1210/er.2016-1007.
[47]	MATT S M, ALLEN J M, LAWSON M A，et al. Butyrate and dietary soluble fiber improve neuroinflammation associated with aging in mice[J]. Front Immunol，2018,9:1832. DOI：10.3389/fimmu.2018.01832.
[48]	ERNY D, HRABE DE ANGELIS A L, JAITIN D，et al. Host microbiota constantly control maturation and function of microglia in the CNS[J]. Nat Neurosci，2015,18(7):965-977. DOI：10.1038/nn.4030.
[49]	SADLER R, CRAMER J V, HEINDL S，et al. Short-chain fatty acids improve poststroke recovery via immunological mechanisms[J]. J Neurosci，2020,40(5):1162-1173. DOI：10.1523/jneurosci.1359-19.2019.
[50]	LIU J M, LI H J, GONG T Y，et al. Anti-neuroinflammatory effect of short-chain fatty acid acetate against Alzheimer's disease via upregulating GPR41 and inhibiting ERK/JNK/NF-κB[J]. J Agric Food Chem，2020,68(27):7152-7161. DOI：10.1021/acs.jafc.0c02807.
[51]	COLOMBO A V, SADLER R K, LLOVERA G，et al. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition[J]. eLife，2021,10:e59826. DOI：10.7554/eLife.59826.
[52]	ERNY D, DOKALIS N, MEZÖ C，et al. Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease[J]. Cell Metab，2021,33(11):2260-2276.e7. DOI：10.1016/j.cmet.2021.10.010.
[53]	LIU J M, WANG F Y, LIU S Z，et al. Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1[J]. J Neurol Sci，2017,381:176-181. DOI：10.1016/j.jns.2017.08.3235.

短链脂肪酸在神经退行性疾病中的相关机制研究进展

Research Advances in the Mechanism of Short-chain Fatty Acids in Neurodegenerative Diseases

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 53

相关文章 15

编辑推荐

Metrics

留言

[1]	梁雪梅, 王睿, 赵玉环, 徐天娇, 王伟, 孙伟东. 经颅低水平激光：一种治疗抑郁症的新方法[J]. 中国全科医学, 2023, 26(27): 3335-3341.
[2]	赵伟, 唐荣杰, 杨珊珊, 杨芳, 孙锋, 廉秋芳. Klotho在盐敏感性高血压肾损伤中的作用及分子机制研究[J]. 中国全科医学, 2023, 26(24): 3042-3049.
[3]	李晓晓, 白艳杰, 王岩, 张雍闯, 陈淑颖, 陈丽敏. 核苷酸结合寡聚化结构域样受体蛋白3炎症小体在脑卒中后认知障碍中的研究进展[J]. 中国全科医学, 2023, 26(17): 2176-2182.
[4]	汪楠, Motuziuk OLEKSANDR, Mishchenko IRYNA, 周颖婷. 酒精性肌病相关炎性因子和氧化应激标志物水平的Meta分析[J]. 中国全科医学, 2022, 25(33): 4123-4129.
[5]	黄朦, 黄存军, 欧秋娟, 戴洪波, 何阶德, 梁航, 陈喆, 徐秋笔. 益生菌干预治疗狼疮肾炎Ⅳ~Ⅴ型患者的效果研究[J]. 中国全科医学, 2022, 25(20): 2462-2467.
[6]	丁志敏, 苏凯奇, 高静, 陈婷玉, 冯一璇, 冯晓东. 线粒体功能障碍与脑卒中后抑郁的关系研究进展[J]. 中国全科医学, 2022, 25(12): 1528-1532.
[7]	曾霖, 张鹏翔, 黄倩, 王高祥, 李惠林. 基于短链脂肪酸防治代谢性疾病的研究进展[J]. 中国全科医学, 2022, 25(09): 1141-1147.
[8]	衡立, 张立国, 董婧婷, 李治国, 曹凤宏. 氧化应激介导雄激素受体信号重激活在前列腺癌演进中的分子机制研究进展[J]. 中国全科医学, 2022, 25(05): 636-642.
[9]	刘环环, 李瑞青, 苏凯奇, 袁洁, 李琪, 冯晓东. 短链脂肪酸对脑卒中的保护作用机制及其与脑卒中后认知障碍关系的研究进展[J]. 中国全科医学, 2022, 25(03): 380-386.
[10]	赵非一，郭盛楠，徐燕，李爱群，宋花玲，李志敏，付强强. 自主运动锻炼是神经退行性疾病的一支“神经保护剂”吗？证据来自临床及临床前研究[J]. 中国全科医学, 2021, 24(5): 517-525.
[11]	宋超杰，张小莉，陈换换. 基于肠道菌群及其代谢产物短链脂肪酸防治1型糖尿病的研究进展[J]. 中国全科医学, 2021, 24(17): 2230-2235.
[12]	胡晓敏，叶佳美，王丽群，庞日朝，王文春，张安仁. 基于肠道菌群探讨运动改善慢性便秘的可能机制[J]. 中国全科医学, 2021, 24(15): 1984-1988.
[13]	王若男，赵德喜，刘立明，牛萍，崔妍，吴九如. 辛伐他汀对脑出血体外模型血肿清除的影响及作用机制研究[J]. 中国全科医学, 2020, 23(23): 2883-2889.
[14]	奚悦，王园媛，崔秀玲. α-硫辛酸在Graves'病合并肝损伤中的保护作用及机制研究[J]. 中国全科医学, 2019, 22(8): 931-935.
[15]	韩广弢，李皓桓，蔡伟松，张宇标. 高胆固醇与骨关节炎的研究进展[J]. 中国全科医学, 2019, 22(32): 4015-4019.